Drug intelligence / Profile preview

AMT-143

Development stage: Discontinued
Lead developer: AmacaThera
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Injectable

Overview

AMT-143 is a non-opioid, injectable biocompatible hydrogel formulation developed by AmacaThera for the treatment of postoperative pain. It utilizes the AmacaGel platform to provide sustained release of a local anesthetic, aiming to reduce opioid dependency and improve surgical outcomes. The drug is administered via syringe at the time of surgery and is designed to offer extended pain relief without opioids.

Other names: AMT 143AMT143AMT-143

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on AMT-143.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMT-143.

Explore the full profile